Abstract
Patients with cystic fibrosis (CF) suffer from chronic lung infection and inflammation leading to respiratory failure. Vitamin D deficiency is common in patients with CF, and correction of vitamin D deficiency may improve innate immunity and reduce inflammation in patients with CF. We conducted a double-blinded, placebo-controlled, randomized clinical trial of high-dose vitamin D to assess the impact of vitamin D therapy on antimicrobial peptide concentrations and markers of inflammation. We randomized 30 adults with CF hospitalized with a pulmonary exacerbation to 250 000 IU of cholecalciferol or placebo, and evaluated changes in plasma concentrations of inflammatory markers and the antimicrobial peptide LL-37 at baseline and 12 weeks post intervention. In the vitamin D group, there was a 50.4% reduction in tumor necrosis factor-α (TNF-α) at 12 weeks (P<0.01), and there was a trend for a 64.5% reduction in interleukin-6 (IL-6) (P=0.09). There were no significant changes in IL-1β, IL-8, IL-10, IL-18BP and NGAL (neutrophil gelatinase-associated lipocalin). We conclude that a large bolus dose of vitamin D is associated with reductions in two inflammatory cytokines, IL-6 and TNF-α. This study supports the concept that vitamin D may help regulate inflammation in CF, and that further research is needed to elucidate the potential mechanisms involved and the impact on clinical outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Elizur A, Cannon CL, Ferkol TW . Airway inflammation in cystic fibrosis. Chest 2008; 133: 489–495.
Jacquot J, Tabary O, Le Rouzic P, Clement A . Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008; 40: 1703–1715.
Hall WB, Sparks AA, Aris RM . Vitamin D deficiency in cystic fibrosis. Int J Endocrinol 2010; 2010: 218691.
McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros 2011; 10: 428–434.
Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD . Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353–361.
Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G . Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D-3. J Cyst Fibros 2007; 6: 403–410.
Grossmann RE, Tangpricha V, Zughaier SM, Liu S . Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: a randomized, controlled trial. Dermato-Endocrinology 2012; 4: 1–8.
Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188: 2127–2135.
Khazai NB, Judd SE, Jeng L, Wolfenden LL, Stecenko A, Ziegler TR et al. Treatment and Prevention of Vitamin D Insufficiency in Cystic Fibrosis Patients: Comparative Efficacy of Ergocalciferol, Cholecalciferol, and UV Light. J Clin Endocrinol Metab 2009; 94: 2037–2043.
Pincikova T, Nilsson K, Moen IE, Karpati F, Fluge G, Hollsing A et al. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr 2011; 65: 102–109.
Acknowledgements
This work was supported in part by the following grants: PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, grant numbers TL1 RR025010 and K23AR054334, and the CF Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Tangpricha received an unrestricted research grant from BTR, Group (a vitamin D supplement company). The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Grossmann, R., Zughaier, S., Liu, S. et al. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr 66, 1072–1074 (2012). https://doi.org/10.1038/ejcn.2012.82
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2012.82
Keywords
This article is cited by
-
Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis
Journal of Health, Population and Nutrition (2024)
-
Vitamin D and idiopathic pulmonary fibrosis: a two-sample mendelian randomization study
BMC Pulmonary Medicine (2023)
-
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia
Current Oncology Reports (2019)
-
Vitamin D supplementation decreases Aspergillus fumigatus specific Th2 responses in CF patients with aspergillus sensitization: a phase one open-label study
Asthma Research and Practice (2015)
-
Determinants of vitamin D deficiency among undergraduate medical students in Saudi Arabia
European Journal of Clinical Nutrition (2015)